Cobellis Luigi, Reis Fernando M, Luisi Stefano, Danero Secondo, Pirtoli Luigi, Scambia Giovanni, Petraglia Felice
Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Siena, Italy.
J Soc Gynecol Investig. 2004 May;11(4):203-6. doi: 10.1016/j.jsgi.2003.10.008.
The aim of the present study was to evaluate the concentrations of activin A in the peritoneal fluid of women with epithelial (serous) ovarian cancer.
A group of 160 women was studied and divided in four subgroups as follows: 1) serous ovarian carcinoma (n = 32); 2) serous ovarian cystadenoma (n = 20); 3) endometriosis (n = 53); and 4) healthy controls (n = 55), including both fertile (n = 32) and postmenopausal women (n = 23). Specimens of peritoneal fluid were collected during surgical interventions, and activin A was quantified using a specific two-site enzyme immunoassay.
Peritoneal fluid activin A concentrations in women with ovarian carcinoma were about five-fold higher than those found in the control group (median [interquartile range] = 7.60 [2.85-10.15] and 1.50 [1.00-2.50] ng/mL, respectively, P <.001). In contrast, the women with benign serous cystadenoma had peritoneal fluid activin A concentrations (1.50 [1.0-2.70] ng/mL) similar to those of the control group. High peritoneal fluid activin A levels (>2 multiples of the mean) distinguished carcinoma from cystadenoma with a sensitivity of 72% and a specificity of 80%. The follow-up of nine patients with stage IIIc ovarian cancer showed no apparent relationship between the peritoneal fluid activin A levels and overall survival. No significant difference in peritoneal fluid activin A concentrations between patients with endometriosis and control women was observed.
Most women with serous ovarian carcinoma had high concentrations of activin A in the peritoneal fluid, supporting a possible role of this growth factor in ovarian cancer.
本研究旨在评估上皮性(浆液性)卵巢癌女性患者腹腔液中激活素A的浓度。
对160名女性进行研究,并分为以下四个亚组:1)浆液性卵巢癌(n = 32);2)浆液性卵巢囊腺瘤(n = 20);3)子宫内膜异位症(n = 53);4)健康对照组(n = 55),包括育龄妇女(n = 32)和绝经后妇女(n = 23)。在手术干预期间收集腹腔液样本,并使用特异性双位点酶免疫测定法定量激活素A。
卵巢癌女性患者腹腔液中激活素A的浓度比对照组高约五倍(中位数[四分位间距]分别为7.60[2.85 - 10.15]和1.50[1.00 - 2.50]ng/mL,P <.001)。相比之下,良性浆液性囊腺瘤女性患者腹腔液中激活素A的浓度(1.50[1.0 - 2.70]ng/mL)与对照组相似。腹腔液中激活素A水平高(>平均水平的2倍)可将癌与囊腺瘤区分开来,敏感性为72%,特异性为80%。对9例IIIc期卵巢癌患者的随访显示,腹腔液中激活素A水平与总生存期之间无明显关系。子宫内膜异位症患者与对照女性之间腹腔液中激活素A浓度无显著差异。
大多数浆液性卵巢癌女性患者腹腔液中激活素A浓度较高,支持这种生长因子在卵巢癌中可能发挥的作用。